Search

for
Search:

GlossaryNivolumab (Opdivo)

immunotherapy drug that helps immune system attack cancer cells

Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1 on the surface of T-cells, which helps the immune system recognize and attack cancer cells more effectively.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 9 results

research Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy

November 2022 in “Journal of the Endocrine Society”

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

research An Industry Update: What's New in the Field of Therapeutic Delivery This Month?

November 2016 in “Therapeutic Delivery”

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

research A Comparative Analysis of Immune Privilege in Pregnancy and Cancer in the Context of Checkpoint Blockade Immunotherapy

16 citations, March 2018 in “Seminars in Oncology”

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

research Cutaneous Manifestations Associated With Immune Checkpoint Inhibitors

14 citations, February 2023 in “Frontiers in immunology”

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.

research Perspectives in Head and Neck Medical Oncology

4 citations, January 2018 in “Cancer treatment and research”

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

View more "opdivo" in research →

Community Join

0 / 0 results

— no results